HUE038049T2 - Eljárások EGFR-inhibitor adagolására - Google Patents

Eljárások EGFR-inhibitor adagolására

Info

Publication number
HUE038049T2
HUE038049T2 HUE11752700A HUE11752700A HUE038049T2 HU E038049 T2 HUE038049 T2 HU E038049T2 HU E11752700 A HUE11752700 A HU E11752700A HU E11752700 A HUE11752700 A HU E11752700A HU E038049 T2 HUE038049 T2 HU E038049T2
Authority
HU
Hungary
Prior art keywords
administering
methods
egfr inhibitor
egfr
inhibitor
Prior art date
Application number
HUE11752700A
Other languages
English (en)
Inventor
Robert Michael Lorence
Mehdi Shahidi
Peter Stopfer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44583460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE038049(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUE038049T2 publication Critical patent/HUE038049T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
HUE11752700A 2010-08-26 2011-08-24 Eljárások EGFR-inhibitor adagolására HUE038049T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37717710P 2010-08-26 2010-08-26

Publications (1)

Publication Number Publication Date
HUE038049T2 true HUE038049T2 (hu) 2018-09-28

Family

ID=44583460

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11752700A HUE038049T2 (hu) 2010-08-26 2011-08-24 Eljárások EGFR-inhibitor adagolására

Country Status (16)

Country Link
US (2) US20130289056A1 (hu)
EP (1) EP2608792B1 (hu)
JP (3) JP2013536244A (hu)
CY (1) CY1119898T1 (hu)
DK (1) DK2608792T3 (hu)
EC (1) ECSP13012523A (hu)
ES (1) ES2655115T3 (hu)
HR (1) HRP20180016T1 (hu)
HU (1) HUE038049T2 (hu)
LT (1) LT2608792T (hu)
NO (1) NO2608792T3 (hu)
PL (1) PL2608792T3 (hu)
PT (1) PT2608792T (hu)
RS (1) RS56682B1 (hu)
SI (1) SI2608792T1 (hu)
WO (1) WO2012027445A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2739436C (en) 2008-10-02 2019-08-27 Salix Pharmaceuticals, Ltd. Use of rifaximin for treating hepatic encephalopathy
WO2012027445A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Methods of administering an egfr inhibitor
CA3121235A1 (en) * 2018-11-30 2020-06-04 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for reducing major thrombotic events in cancer patients

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
CA2445967A1 (en) * 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10307165A1 (de) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20070009533A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
CA2629249C (en) * 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
WO2007054550A1 (en) * 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
EP1981863B1 (en) 2006-01-26 2012-10-10 Boehringer Ingelheim International GmbH Process for preparing aminocrotonylamino-substituted quinazoline derivatives
DK2068880T3 (da) 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
WO2008121467A2 (en) 2007-02-28 2008-10-09 Dana-Farber Cancer Institute, Inc. Combination therapy for treating cancer
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
WO2012027445A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Methods of administering an egfr inhibitor

Also Published As

Publication number Publication date
SI2608792T1 (en) 2018-02-28
EP2608792B1 (en) 2017-10-11
NO2608792T3 (hu) 2018-03-10
JP6541637B2 (ja) 2019-07-10
JP2013536244A (ja) 2013-09-19
PT2608792T (pt) 2018-01-15
RS56682B1 (sr) 2018-03-30
US20130289056A1 (en) 2013-10-31
EP2608792A1 (en) 2013-07-03
US20160287591A1 (en) 2016-10-06
HRP20180016T1 (hr) 2018-02-09
ECSP13012523A (es) 2013-05-31
JP2017081966A (ja) 2017-05-18
WO2012027445A1 (en) 2012-03-01
JP2019147814A (ja) 2019-09-05
LT2608792T (lt) 2018-01-10
PL2608792T3 (pl) 2018-03-30
ES2655115T3 (es) 2018-02-16
DK2608792T3 (en) 2018-01-15
CY1119898T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
AP3907A (en) 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
EP2637502A4 (en) MUTANT-SELECTIVE EGFR HEMMER AND USES THEREOF
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
PT2539136T (pt) Poste de barreira e método de fabrico do mesmo
EP2675458A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
IL226352A0 (en) שקיטה@לטיפול@עם@מעקב@braf
PT2670401E (pt) Métodos de utilização de inibidores de alk
ZA201206456B (en) Uses of dgati inhibitors
IL256026A (en) Treatment methods
EP2536709A4 (en) PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2688901A4 (en) INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10
EP2635287A4 (en) NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
IL222360A0 (en) Method of vaccination
RS56682B1 (sr) Postupci primene egfr inhibitora
EP2879681A4 (en) INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
ZA201303359B (en) Method of treatment with braf inhibitor
GB201019938D0 (en) Determination of therapeutic agents
GB201004059D0 (en) Method of construction
AU2011903137A0 (en) Compounds and methods of their use - IV